Abstracts tagged "pregnancy"

Abstract Number: 0979 • ACR Convergence 2023
Use and Discontinuation of Tumour Necrosis Factor Inhibitors Among Pregnant Women with Chronic Inflammatory Diseases
Leah K. Flatman¹, Sasha Bernatsky², Isabelle Malhamé³, Yvan St. Pierre², Olga Basso¹, Anick Bérard⁴ and Evelyne Vinet⁵, ¹McGill University, Montreal, QC, Canada, ²Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³McGill University Health Centre, Montreal, QC, Canada, ⁴University of Montreal, Montreal, QC, Canada, ⁵McGill University Health Centre, Montréal, QC, Canada
Background/Purpose: Early consensus statements recommended discontinuing tumour necrosis factor inhibitors (TNFi) during pregnancy. Despite new guidelines recommending against this, the choice to stop TNFi pre-conception…
Abstract Number: 1571 • ACR Convergence 2023
Tocilizumab in Pregnant Takayasu Arteritis – The Use of Tocilizumab at Conception and Throughout Pregnancy in Those with Takayasu Arteritis
Nurul Aulia Zakaria¹, Andrew Porter², Robert Maughan², Charis Pericleous², Japna Satara³, Matthew Colquhoun⁴, Priyanka Agrawal³, jan Nouza³, Harold Wilson-Morkeh³, Taryn Youngstein² and Justin Mason², ¹National Heart & Lung Institute, Imperial College London, Kuantan, Malaysia, ²National Heart & Lung Institute, Imperial College London, London, United Kingdom, ³Rheumatology, Hammersmith Hospital, London, United Kingdom, ⁴Department of Rheumatology, Imperial College Healthcare Trust, London, United Kingdom
Background/Purpose: Takayasu arteritis (TA) is a large vessel vasculitis predominantly affecting female of reproductive age. Tocilizumab (TCZ) is frequently used in synthetic DMARD refractory cases.…
Abstract Number: 0464 • ACR Convergence 2023
Adverse Pregnancy Outcomes in Sjogren’s Disease Compared to Controls: An Interdisciplinary Approach with Maternal Fetal Medicine
Lauren Tesoriero¹, Jennifer Kidd¹, Julie Piccione¹, Izmirly peter², Meredith Akerman¹, Steven Carsons¹, Patricia Rekawek¹ and Julie Nusbaum¹, ¹NYU Long Island School of Medicine, Mineola, NY, ²NYU, New York, NY
Background/Purpose: Outside of the known association of Ro antibody with congenital heart block (CHB), little is known about adverse maternal outcomes, and even less about…
Abstract Number: 0986 • ACR Convergence 2023
Medication Use Patterns and Factors Associated with Abnormal Pregnancy Outcomes in Patients with Rheumatoid Arthritis in Korea
Yeo-Jin Song¹, Soo-Kyung Cho¹, Yu-Seon Jung², Jihyun Keum³, Sun-Young Jung², Dae Hyun Yoo⁴ and Yoon-Kyoung Sung¹, ¹Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²College of Pharmacy, Chung-Ang University, Seoul, South Korea, ³Department of Obstetrics and Gynecology, College of Medicine, Hanyang University, Seoul, South Korea, ⁴Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea
Background/Purpose: As female patients constitute a significant proportion of rheumatoid arthritis (RA) cases, pregnancy management is crucial for women with RA. This study aimed to…
Abstract Number: 1681 • ACR Convergence 2023
Tacrolimus Use in SLE Pregnancy and Its Effect on Pregnancy Outcomes: Retrospective Study in Two Japanese Tertiary Referral Centers
Takehiro Nakai¹, Nanase Honda², Eri Soga², Sho Fukui³, Ayako Kitada¹, Naoto Yokogawa⁴ and Masato Okada¹, ¹St. Luke's International Hospital, Tokyo, Japan, ²Tokyo Metropolitan Tama Medical Center, Tama, Japan, ³Brigham and Women's Hospital, Boston, MA, ⁴Tokyo Metropolitan Tama Medical Center, Taito City, Tokyo, Japan
Background/Purpose: Tacrolimus is one of the major treatment options of systemic lupus erythematosus (SLE) and is thought to be pregnancy compatible medication. Since little is…
Abstract Number: L13 • ACR Convergence 2022
Fetal Cardiac Targets Identify the Autoantibodies Associated with Congenital Heart Block
Stephanie Benjamin¹, Lisa Vi², Diptendu Chatterjee¹, Edgar Jaeggi¹, Marie Wahren-Herlenius³, Amelia Ruffatti⁴, Linda Hiraki⁵, Michelle Lohbihler², Lusia Sepiashvili¹, Carl Laskin⁶, Meena Fatah¹, Daniela Dominguez⁵, Lawrence Ng⁵, Anthony Gramolini², Vincent Christoffels⁷, Stephanie Protze² and Robert Hamilton⁸, ¹Hospital for Sick Children, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Karolinska Institutet, Stockholm, Stockholms Lan, Sweden, ⁴Universitå di Padova, Padova, Italy, ⁵The Hospital for Sick Children, Toronto, ON, Canada, ⁶Mt. Sinai Hospital/University of Toronto, Toronto, ON, Canada, ⁷Amsterdam UMC, Amsterdam, Zuid-Holland, Netherlands, ⁸Hospital for Sick Children, Markham, ON, Canada
Background/Purpose: Autoimmune congenital heart block (CHB+) affects the fetus of mothers with anti-Ro antibodies. Anti-Ro (Ro+) antibodies (Abs) are usually present in maternal sera when…
Abstract Number: 0955 • ACR Convergence 2022
Unfavorable Pregnancy Outcome Is Significantly Associated with Corticosteroid Exposure During Pregnancy in Women with RA: Analysis of the Prospective GR2 Cohort
SABRINA HAMROUN¹, Marion Couderc², Rene-Marc Flipo³, Laure Gossec⁴, Christophe Richez⁵, Rakiba Belkhir⁶, Aline Frazier-Mironer⁷, Valerie Devauchelle⁸, Hubert Marotte⁹, Jérémie SELLAM¹⁰, elisabeth gervais¹¹, Alban DEROUX¹², Cédric Lukas¹³, Emmanuelle Dernis¹⁴, Emmanuel Chatelus¹⁵ and Anna Molto¹⁶, ¹Rheumatology Department, University Hospital of Cochin, Paris, Paris, France, ²University Hospital, Clermont-Ferrand, France, ³CHU Lille, Boulogne-Billancourt, France, ⁴Sorbonne Université, Paris, France, ⁵Université de Bordeaux, Bordeaux, France, ⁶Rheumatology departement, Bicêtre, Paris-Saclay university, Le Kremlin Bicêtre, France, ⁷APHP Hôpital Lariboisire, Paris, France, ⁸Université de Bretagne Occidentale, Brest, France, ⁹INSERM 1059, Saint-Etienne, France, ¹⁰Sorbonne Universite, AP-HP, Saint-Antoine hospital, Paris, France, ¹¹chu poitiers, Poitiers, France, ¹²CHU Grenoble, Grenoble, France, ¹³University Hospital Centre Montpellier, University of Montpellier, Montpellier, France, ¹⁴LE MANS general hospital, LE MANS, France, ¹⁵University Hospital of Strasbourg, Strasbourg, France, ¹⁶Rheumatology Department, Cochin Hospital, APHP, Paris, France
Background/Purpose: Rheumatoid arthritis (RA) is one of the most common chronic inflammatory diseases and regularly affects women of childbearing age. However, there is limited knowledge…
Abstract Number: 1672 • ACR Convergence 2022
The Impact of Systemic Sclerosis (SSc) on Women’s Health Evaluated with a New SSc-specific Patient-reported Questionnaire
Maria Grazia Lazzaroni¹, Liala Moschetti¹, Eleonora Pedretti¹, Andrea Lojacono², Francesca Ramazzotto³, Cristina Zanardini³, Zatti Sonia³, Angela Tincani⁴, Franco Franceschini¹, Paolo Airò⁵ and Laura Andreoli¹, ¹Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Brescia, Italy, ²Obstetrics and Gynecology, ASST Garda, Desenzano del Garda, Brescia, Brescia, Italy, ³Obstetrics and Gynecology, ASST Spedali Civili and University of Brescia, Brescia, Italy, ⁴Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Gussago, Italy, ⁵Rheumatology and Clinical Immunology Unit, ASST Spedali Civili, Brescia, Italy
Background/Purpose: Systemic Sclerosis (SSc) has a strong female predominance and can significantly impair the everyday quality of life of patients. We aimed at designing a…
Abstract Number: 0956 • ACR Convergence 2022
Contribution of Antibody Titers/Specificities to Adverse Pregnancy Outcomes in a Multicenter Prospective Study of anti-Ro Positive Mothers
Nicola Fraser¹, Mala Masson², Kristina Deonaraine³, Philip Carlucci⁴, Colin Phoon⁵, Ashley Roman⁵, Peter Izmirly⁶, Amit Saxena⁵, Michael Belmont⁶, Christina Penfield⁵, Young Mi Lee⁵, Julie Nusbaum⁷, Bruce Solitar⁵, Fardina Malik⁵, Paula Rackoff¹, Rebecca Haberman¹, Ruben Acherman⁸, Elena Sinkovskaya⁹, Alfred Albuhamad⁹, Majd Makhoul¹⁰, Gary Satou¹¹, Nelangi Pinto¹², Anita Moon-Grady¹³, Lisa Howley¹⁴, Stephanie Levasseur¹⁵, Jyothi Matta¹⁶, Christopher Lindblade¹⁷, Andrew Rubenstein¹⁸, Caitlin Haxel¹⁹, Katherine Kohari²⁰, Joshua Copel²⁰, James Strainic²¹, Tam Doan²², Karla Bermudez-Wagner²², Shreya Sunil Sheth²², Stacy Killen²³, Theresa Tacy²⁴, Michelle Kaplinski²⁴, Bailey Drewes²⁵, Robert Clancy⁶, Bettina Cuneo²⁶ and Jill Buyon⁶, ¹NYU School of Medicine, New York, NY, ²NYU Langone Medical Center- Division of Rheumatology, New York, NY, ³University at Buffalo, Buffalo, NY, ⁴NYU Langone, New York, NY, ⁵NYU Langone Health, New York, NY, ⁶NYU Grossman School of Medicine, New York, NY, ⁷NYU Long Island School of Medicine, Mineola, NY, ⁸Children's Heart Center, Las Vegas, ⁹East Virginia Medical School, Norfolk, VA, ¹⁰University of Kentucky, Lexington, KY, ¹¹University of California Los Angeles, Los Angeles, CA, ¹²University of Utah, Salt Lake City, ¹³UCSF, San Francisco, ¹⁴Midwest Fetal Care Center, Children's Minnesota/Allina Health, Minneapolis, MN, ¹⁵Columbia University, New York, NY, ¹⁶University of Louisville, Louisville, KY, ¹⁷Phoenix Children's Hospital, Phoenix, ¹⁸Dignity Health, Phoenix, ¹⁹University of Vermont Children's Hospital, Burlington, VT, ²⁰Yale University, New Haven, CT, ²¹UH Rainbow Babies, Cleveland, OH, ²²Baylor College of Medicine, Houston, TX, ²³Vanderbilt University, Nashville, TN, ²⁴Stanford University, Stanford, CA, ²⁵University of Colorado, Denver, CO, ²⁶University of Colorado School of Medicine, Aurora, CO
Background/Purpose: While it is well accepted that congenital heart block (CHB) and neonatal annular rash are highly associated with maternal anti-Ro60 and 52 autoantibodies, the…
Abstract Number: 1673 • ACR Convergence 2022
Preconceptional NSAID Treatment Exposure Is Associated with a Significantly Longer Time-to-conception in Women with Spondyloarthritis: Analysis of the Prospective GR2 Cohort
SABRINA HAMROUN¹, Marion Couderc², Rene-Marc Flipo³, Jérémie SELLAM⁴, Christophe Richez⁵, Emmanuelle Dernis⁶, Aline Frazier-Mironer⁷, Laure Gossec⁸, elisabeth gervais⁹, Hubert Marotte¹⁰, Laetitia Dunogeant¹¹, Cédric Lukas¹², Alban DEROUX¹³, Nathalie Costedoat-Chalumeau¹⁴ and Anna Molto¹⁵, ¹Rheumatology Department, University Hospital of Cochin, Paris, Paris, France, ²University Hospital, Clermont-Ferrand, France, ³CHU Lille, Boulogne-Billancourt, France, ⁴Sorbonne Universite, AP-HP, Saint-Antoine hospital, Paris, France, ⁵Université de Bordeaux, Bordeaux, France, ⁶LE MANS general hospital, LE MANS, France, ⁷APHP Hôpital Lariboisire, Paris, France, ⁸Sorbonne Université, Paris, France, ⁹chu poitiers, Poitiers, France, ¹⁰INSERM 1059, Saint-Etienne, France, ¹¹Hospital of Aix en Provence, Marseille, France, ¹²University Hospital Centre Montpellier, University of Montpellier, Montpellier, France, ¹³CHU Grenoble, Grenoble, France, ¹⁴Inserm DR Paris 5, Paris, France, ¹⁵Rheumatology Department, Cochin Hospital, APHP, Paris, France
Background/Purpose: Spondyloarthritis (SpA) is one of the most common chronic inflammatory diseases and regularly affects women of childbearing age. However, there is limited knowledge about…
Abstract Number: 0957 • ACR Convergence 2022
Timeliness of Fetal Echocardiography for Congenital Heart Block Detection in Anti-Ro/La-Positive Pregnancies
Amanda Ohayon¹, Nikola Wilk¹, Arielle Mendel², Mayssa Moukarzel¹, Jessica Simoneau¹, Wadi Mawad¹, Gabriel Altit¹ and Evelyne Vinet², ¹McGill University Health Center, Montréal, QC, Canada, ²McGill University Health Centre, Montréal, QC, Canada
Background/Purpose: Best practice guidelines recommend screening for congenital heart block (CHB) in anti-Ro/La-positive pregnancies with serial echocardiography starting between 16 to 18 weeks of gestational…
Abstract Number: 1674 • ACR Convergence 2022
In Utero Exposure to Hydroxychloroquine Does Not Associate with Ocular Toxicity as Assessed by Optical Coherence Tomography Five Years After Birth
Peter Izmirly¹, Mala Masson², Michael Marmor³, Noel Zahr⁴, Nathalie Costedoat-Chalumeau⁵ and Jill Buyon¹, ¹NYU Grossman School of Medicine, New York, NY, ²NYU Langone Medical Center- Division of Rheumatology, New York, NY, ³Stanford University, Stanford, CA, ⁴Pitié-Salpêtrière Hospital, Paris, France, ⁵Inserm DR Paris 5, Paris, France
Background/Purpose: The preventive approach to congenital heart block with hydroxychloroquine (HCQ) [PATCH] study supported the efficacy of HCQ to reduce the recurrence rate of cardiac…
Abstract Number: 0958 • ACR Convergence 2022
Azathioprine Metabolite Levels and Outcomes During Pregnancies in Women with Rheumatic Disease
Stephen Balevic¹, Catherine Sims², Amanda Eudy³ and Megan Clowse², ¹Duke Clinical Research Institute, Durham, NC, ²Duke University, Durham, NC, ³Duke University, Raleigh, NC
Background/Purpose: Despite the wide use of AZA during pregnancy, there are no studies evaluating the impact of pregnancy on AZA metabolites 6-thioguanine nucleotide (6-TGN) and…
Abstract Number: 2022 • ACR Convergence 2022
Outcome of Pregnancy in Women with Primary Sjögren’s Syndrome Compared to the General Population: The French Multicenter Prospective GR2 Study
Gregoire Martin de Fremont¹, Nathalie Costedoat-Chalumeau², Rakiba Belkhir³, Gaelle Guettrot-Imbert⁴, Nathalie Morel⁴, Gaetane Nocturne⁵, Anna Molto⁶, Tiphaine Goulenok⁷, Elisabeth Diot⁸, Estibaliz Lazaro⁹, Laurent Perard¹⁰, Nicole Ferreira¹¹, Maelle Le Besnerais¹², Nicolas Limal⁷, Nihal Martis¹³, Noémie Abisror¹⁴, Odile Debouverie¹⁵, Christophe Richez¹⁶, Vincent Sobanski¹⁷, Francois Maurier¹⁸, Gaetan Sauvetre¹², Herve Levesque¹², Marie Agnes Timsit¹⁹, Nathalie Tieule¹³, Pauline Orquevaux²⁰, GEFA Collaborative group²¹, Matthieu Mahevas²², Celine Lartigau Roussin²³, Elodie Chauvet²⁴, Emilie Berthoux²⁵, Francoise Sarrot Reynauld²⁶, Loic Raffray²⁷, Marion Couderc²⁸, Nicolas Martin Silva²⁹, Noemie Jourde Chiche³⁰, Nicolas Belhomme³¹, Thierry Thomas³², Vincent Poindron³³, Viviane Queyrel¹³, Juliette Delforge³⁴, Camille Le Ray³⁵, Emmanuelle Pannier³⁵, Xavier Mariette³⁶, Veronique Le Guern⁴ and Raphaèle Seror³⁷, ¹Rheumatology department, Kremlin Bicêtre hospital, APHP, Paris, France, ²Inserm DR Paris 5, Paris, France, ³Rheumatology departement, Bicêtre, Paris-Saclay university, Le Kremlin Bicêtre, France, ⁴Hôpital Cochin, Paris, France, ⁵APHP, Le Kremlin Bicêtre, France, ⁶Rheumatology Department, Cochin Hospital, APHP, Paris, France, ⁷APHP, Paris, France, ⁸CHU Tours, Tours, France, ⁹Bordeaux Hospital University, Bordeaux, France, ¹⁰CHU Lyon, Lyon, France, ¹¹department of Internal Medecine, CHU de Tours, Tours, France, ¹²CHU Rouen, Rouen, France, ¹³CHU Nice, Nice, France, ¹⁴Hopital Saint Antoine, Paris, France, ¹⁵CHU Poitiers, Poitiers, France, ¹⁶Université de Bordeaux, Bordeaux, France, ¹⁷Université de Lille, Lille, France, ¹⁸Hôpitaux privés de Metz, Metz, France, ¹⁹CHU Brest, Brest, France, ²⁰CHU Reims, Reims, France, ²¹Saint Joseph Hospital, Marseille, France, ²²CHU Mondor, Creteil, France, ²³CH La Réunion, CH la Réunion, France, ²⁴CH Cabestany, Cabestany, France, ²⁵CH Saint Joseph Saint Luc, Lyon, France, ²⁶CHU Grenoble, CHU Grenoble, France, ²⁷CH St Denis Reunion, Saint Denis Reunion, France, ²⁸University Hospital, Clermont-Ferrand, France, ²⁹CHU Caen, Caen, France, ³⁰APHM, Marseille, France, ³¹CHU Rennes, Rennes, France, ³²CHU Saint Etienne, Saint Etienne, France, ³³Immunologie clinique et médecine interne, Hôpitaux universitaires de Strasbourg, Strasbourg, France, ³⁴Jean Verfier, Bobigny, France, ³⁵Port Royal, Paris, France, ³⁶Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, ³⁷University Hospital Paris-Saclay, Le Kremlin Bicêtre, France
Background/Purpose: In the context of primary Sjögren's syndrome (pSS), only a few retrospective studies using heterogeneous methods have investigated the risk of adverse pregnancy outcomes…
Abstract Number: 0320 • ACR Convergence 2022
Metabolomics in Systemic Lupus Erythematosus and Pregnancy – A Prospective Observational Longitudinal Study
Shi-Nan Luong¹, Isabella Sheldon², Charles Raine³, Elizabeth Jury³ and Ian Giles³, ¹University College London, United Kingdom and University of New South Wales, Sydney, Australia, ²London School of Hygiene and Tropical Medicine, London, United Kingdom, ³University College London, London, United Kingdom
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterised by activation of immunological and cellular pathways, disease flares and adverse pregnancy outcomes (APO). Metabolomic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].